# Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

> **NCT05057247** · PHASE2 · COMPLETED · sponsor: **Glenn J. Hanna** · enrollment: 26 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Recurrent Squamous Cell Carcinoma of the Head and Neck
- Metastatic Head and Neck Cancer
- Advanced Head and Neck Cancer
- Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05057247
- **Lead sponsor:** Glenn J. Hanna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2023-10-01
- **Final completion:** 2024-06-13
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057247, "Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05057247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*